CN107106678A - 用于治疗患有高胆固醇血症的高心血管风险患者的方法 - Google Patents

用于治疗患有高胆固醇血症的高心血管风险患者的方法 Download PDF

Info

Publication number
CN107106678A
CN107106678A CN201580049703.6A CN201580049703A CN107106678A CN 107106678 A CN107106678 A CN 107106678A CN 201580049703 A CN201580049703 A CN 201580049703A CN 107106678 A CN107106678 A CN 107106678A
Authority
CN
China
Prior art keywords
patient
antibody
patients
dose
ldl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580049703.6A
Other languages
English (en)
Chinese (zh)
Inventor
C·阿诺汀
L·贝萨克
U·乔杜里
R·波尔迪
D·A·施韦默尔吉普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Priority to CN202111397525.XA priority Critical patent/CN114306592A/zh
Publication of CN107106678A publication Critical patent/CN107106678A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580049703.6A 2014-07-16 2015-07-16 用于治疗患有高胆固醇血症的高心血管风险患者的方法 Pending CN107106678A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111397525.XA CN114306592A (zh) 2014-07-16 2015-07-16 用于治疗患有高胆固醇血症的高心血管风险患者的方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201462025371P 2014-07-16 2014-07-16
US62/025,371 2014-07-16
US201462043167P 2014-08-28 2014-08-28
US62/043,167 2014-08-28
US201462080725P 2014-11-17 2014-11-17
US62/080,725 2014-11-17
US201562132709P 2015-03-13 2015-03-13
US62/132,709 2015-03-13
EP15305830 2015-05-29
EP15305830.0 2015-05-29
PCT/US2015/040765 WO2016011260A1 (en) 2014-07-16 2015-07-16 Methods for treating high cardiovascular risk patients with hypercholesterolemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111397525.XA Division CN114306592A (zh) 2014-07-16 2015-07-16 用于治疗患有高胆固醇血症的高心血管风险患者的方法

Publications (1)

Publication Number Publication Date
CN107106678A true CN107106678A (zh) 2017-08-29

Family

ID=53365943

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580049703.6A Pending CN107106678A (zh) 2014-07-16 2015-07-16 用于治疗患有高胆固醇血症的高心血管风险患者的方法
CN202111397525.XA Pending CN114306592A (zh) 2014-07-16 2015-07-16 用于治疗患有高胆固醇血症的高心血管风险患者的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111397525.XA Pending CN114306592A (zh) 2014-07-16 2015-07-16 用于治疗患有高胆固醇血症的高心血管风险患者的方法

Country Status (12)

Country Link
US (2) US20160137746A1 (https=)
EP (2) EP3169362B1 (https=)
JP (1) JP6912374B2 (https=)
KR (3) KR20230007538A (https=)
CN (2) CN107106678A (https=)
AU (1) AU2015289617B2 (https=)
CA (1) CA2955304C (https=)
MX (2) MX378872B (https=)
PL (1) PL3169362T3 (https=)
RU (1) RU2723018C2 (https=)
WO (1) WO2016011260A1 (https=)
ZA (1) ZA201700196B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021098720A1 (zh) * 2019-11-18 2021-05-27 康融东方（广东）医药有限公司 抗pcsk9抗体及其应用
CN113015543A (zh) * 2018-03-06 2021-06-22 赛诺菲生物技术公司 Pcsk9抑制剂用于降低心血管风险的用途
CN116096365A (zh) * 2020-08-07 2023-05-09 瑞泽恩制药公司 涉及angptl3抑制剂的治疗难治性高胆固醇血症的方法
WO2025067337A1 (zh) * 2023-09-28 2025-04-03 康霖生物科技（杭州）有限公司 用于基因治疗的核酸构建体及其用途
US12281173B2 (en) 2016-03-03 2025-04-22 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in combination with an ANGPTL3 inhibitor
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
SG192117A1 (en) 2011-01-28 2013-08-30 Sanofi Sa Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
HUE069234T2 (hu) 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US10494442B2 (en) 2013-06-07 2019-12-03 Sanofi Biotechnology Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
CN118105480A (zh) 2013-11-12 2024-05-31 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
WO2016046684A1 (en) * 2014-09-23 2016-03-31 Pfizer Inc. Treatment with anti-pcsk9 antibodies
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
TW201904608A (zh) * 2017-06-09 2019-02-01 法商賽諾菲生物技術公司 藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法
MX2021008661A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245641A (zh) * 2008-12-15 2011-11-16 瑞泽恩制药公司 抗pcsk9的高亲和力人抗体
EP2706070A1 (en) * 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
CN103841992A (zh) * 2011-05-10 2014-06-04 安姆根有限公司 治疗或预防胆固醇相关疾病的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
SG192117A1 (en) * 2011-01-28 2013-08-30 Sanofi Sa Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
US20130006482A1 (en) * 2011-06-30 2013-01-03 Ramadev Burigsay Hukkeri Guidance system for a mobile machine
HUE069234T2 (hu) * 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
EA039310B1 (ru) * 2015-02-26 2022-01-12 Санофи Байотекнолоджи Способы снижения сердечно-сосудистого риска

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245641A (zh) * 2008-12-15 2011-11-16 瑞泽恩制药公司 抗pcsk9的高亲和力人抗体
CN103841992A (zh) * 2011-05-10 2014-06-04 安姆根有限公司 治疗或预防胆固醇相关疾病的方法
EP2706070A1 (en) * 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ATSUSHI HIRAYAMA等: "Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk--Primary Results From the Phase 2 YUKAWA Study", 《CIRC J》 *
FREDERICK RAAL 等: "Low-density Lipoprotein Cholesterol-Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibitio", 《CIRCULATION》 *
JAMES M等: "Safety and Efficacy of a Monoclonal Antibody to", 《J AM COLL CARDIOL》 *
JOHN J. P. KASTELEIN等: "Efficacy and Safety of Alirocumab in Patients", 《CARDIOVASC DRUGS THER》 *
LYNNE LEDERMAN: "Monoclonal Antibody to PCSK9 Offers New Approach to Treating Hypercholesterolemia", 《MD CONFERENCE EXPRESS》 *
金征宇: "《多层螺旋CT影像诊断学》", 31 May 2009, 科学技术文献出版社 *
韩旭等: "PCFK9在血脂调节中的研究进展", 《国际心血管病杂志》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12281173B2 (en) 2016-03-03 2025-04-22 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in combination with an ANGPTL3 inhibitor
CN113015543A (zh) * 2018-03-06 2021-06-22 赛诺菲生物技术公司 Pcsk9抑制剂用于降低心血管风险的用途
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
WO2021098720A1 (zh) * 2019-11-18 2021-05-27 康融东方（广东）医药有限公司 抗pcsk9抗体及其应用
CN116096365A (zh) * 2020-08-07 2023-05-09 瑞泽恩制药公司 涉及angptl3抑制剂的治疗难治性高胆固醇血症的方法
WO2025067337A1 (zh) * 2023-09-28 2025-04-03 康霖生物科技（杭州）有限公司 用于基因治疗的核酸构建体及其用途

Also Published As

Publication number Publication date
AU2015289617B2 (en) 2021-04-15
CA2955304C (en) 2023-12-12
RU2017104799A (ru) 2018-08-16
KR20240132123A (ko) 2024-09-02
RU2017104799A3 (https=) 2019-02-19
ZA201700196B (en) 2024-09-25
EP3169362A1 (en) 2017-05-24
EP3169362B1 (en) 2020-06-10
PL3169362T3 (pl) 2020-12-28
KR102482375B1 (ko) 2022-12-29
MX378872B (es) 2025-03-11
KR20230007538A (ko) 2023-01-12
WO2016011260A1 (en) 2016-01-21
RU2723018C2 (ru) 2020-06-08
CA2955304A1 (en) 2016-01-21
JP2017522316A (ja) 2017-08-10
CN114306592A (zh) 2022-04-12
MX2017000628A (es) 2017-04-27
US20160137746A1 (en) 2016-05-19
AU2015289617A1 (en) 2017-02-02
US20200255544A1 (en) 2020-08-13
KR20170028441A (ko) 2017-03-13
EP3753575A1 (en) 2020-12-23
JP6912374B2 (ja) 2021-08-04
MX2021000289A (es) 2021-03-31

Similar Documents

Publication Publication Date Title
JP7467538B2 (ja) ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法
CN107106678A (zh) 用于治疗患有高胆固醇血症的高心血管风险患者的方法
US20220144969A1 (en) Methods for reducing cardiovascular risk
TW201536315A (zh) 治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症之方法
HK1236135B (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
HK1236135A1 (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
HK1232890A1 (en) Methods for reducing cardiovascular risk

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170829

RJ01 Rejection of invention patent application after publication